Prime Medicine, Inc.
PRME · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $155 | $148 | $87 | $71 |
| G&A Expenses | $50 | $43 | $30 | $14 |
| SG&A Expenses | $50 | $43 | $30 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $14 | $0 | $0 |
| Operating Expenses | $205 | $205 | $117 | $84 |
| Operating Income | -$202 | -$205 | -$117 | -$84 |
| % Margin | -6,787.4% | – | – | – |
| Other Income/Exp. Net | $7 | $6 | -$6 | -$81 |
| Pre-Tax Income | -$196 | -$198 | -$123 | -$166 |
| Tax Expense | $0 | -$0 | -$1 | -$0 |
| Net Income | -$196 | -$198 | -$122 | -$165 |
| % Margin | -6,566.6% | – | – | – |
| EPS | -1.652 | -2.178 | -1.461 | -1.923 |
| % Growth | 24.2% | -49.1% | 24% | – |
| EPS Diluted | -1.652 | -2.178 | -1.461 | -1.923 |
| Weighted Avg Shares Out | 119 | 91 | 97 | 96 |
| Weighted Avg Shares Out Dil | 119 | 91 | 97 | 96 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $5 | $2 | $1 |
| EBITDA | -$196 | -$187 | -$114 | -$84 |
| % Margin | -6,581.9% | – | – | – |